As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback